Theranostic nanoparticles.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 25413134.
- Also identified by DOI 10.2967/jnumed.114.146019 and PMC identifier 4255955.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Theranostic nanoparticles hold the potential to revolutionize disease management. Over the last decade, there has been growing interest in the engineering of various kinds of theranostic nanoparticles for simultaneous cancer imaging and therapy in small animals. Efficient targeting of theranostic nanoparticles to the tumor site is critical for both diagnosis and therapy. However, difficulties still exist in the engineering of biocompatible theranostic nanoparticles with highly specific in vivo tumor-targeting capabilities. Here, we discuss the current and prospective status of theranostic nanoparticles that actively target tumors, as well as the challenges that still exist.
Medical subject headings
- Humans
- Nanoparticles
- Nanoparticles/chemistry
- Nanoparticles/therapeutic use
- Neoplasms
- Neoplasms/diagnostic imaging
- Radionuclide Imaging
- Radiopharmaceuticals
- Radiopharmaceuticals/administration & dosage
- Radiopharmaceuticals/chemical synthesis